Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Signal Transduct Target Ther ; 8(1): 300, 2023 08 14.
Article in English | MEDLINE | ID: mdl-37574471

ABSTRACT

As a family of cationic host defense peptides, defensins are mainly synthesized by Paneth cells, neutrophils, and epithelial cells, contributing to host defense. Their biological functions in innate immunity, as well as their structure and activity relationships, along with their mechanisms of action and therapeutic potential, have been of great interest in recent years. To highlight the key research into the role of defensins in human and animal health, we first describe their research history, structural features, evolution, and antimicrobial mechanisms. Next, we cover the role of defensins in immune homeostasis, chemotaxis, mucosal barrier function, gut microbiota regulation, intestinal development and regulation of cell death. Further, we discuss their clinical relevance and therapeutic potential in various diseases, including infectious disease, inflammatory bowel disease, diabetes and obesity, chronic inflammatory lung disease, periodontitis and cancer. Finally, we summarize the current knowledge regarding the nutrient-dependent regulation of defensins, including fatty acids, amino acids, microelements, plant extracts, and probiotics, while considering the clinical application of such regulation. Together, the review summarizes the various biological functions, mechanism of actions and potential clinical significance of defensins, along with the challenges in developing defensins-based therapy, thus providing crucial insights into their biology and potential clinical utility.


Subject(s)
Inflammatory Bowel Diseases , Paneth Cells , Animals , Humans , Paneth Cells/metabolism , Inflammatory Bowel Diseases/metabolism , Defensins/genetics , Defensins/metabolism
3.
Biomed Res Int ; 2019: 7084734, 2019.
Article in English | MEDLINE | ID: mdl-30941370

ABSTRACT

Butyrate produced by the intestinal microbiota is essential for proper functioning of the intestinal immune system. Total dependence on parenteral nutrition (PN) is associated with numerous adverse effects, including severe microbial dysbiosis and loss of important butyrate producers. We hypothesised that a lack of butyrate produced by the gut microbiota may be compensated by its supplementation in PN mixtures. We tested whether i.v. butyrate administration would (a) positively modulate intestinal defence mechanisms and (b) counteract PN-induced dysbiosis. Male Wistar rats were randomised to chow, PN, and PN supplemented with 9 mM butyrate (PN+But) for 12 days. Antimicrobial peptides, mucins, tight junction proteins, and cytokine expression were assessed by RT-qPCR. T-cell subpopulations in mesenteric lymph nodes (MLN) were analysed by flow cytometry. Microbiota composition was assessed in caecum content. Butyrate supplementation resulted in increased expression of tight junction proteins (ZO-1, claudin-7, E-cadherin), antimicrobial peptides (Defa 8, Rd5, RegIIIγ), and lysozyme in the ileal mucosa. Butyrate partially alleviated PN-induced intestinal barrier impairment and normalised IL-4, IL-10, and IgA mRNA expression. PN administration was associated with an increase in Tregs in MLN, which was normalised by butyrate. Butyrate increased the total number of CD4+ and decreased a relative amount of CD8+ memory T cells in MLN. Lack of enteral nutrition and PN administration led to a shift in caecal microbiota composition. Butyrate did not reverse the altered expression of most taxa but did influence the abundance of some potentially beneficial/pathogenic genera, which might contribute to its overall beneficial effect.


Subject(s)
Butyrates/pharmacology , Dietary Supplements , Gastrointestinal Microbiome , Intestines/pathology , Parenteral Nutrition , Animals , Biodiversity , Colon/drug effects , Colon/pathology , Gastrointestinal Microbiome/drug effects , Gene Expression Regulation/drug effects , Ileum/drug effects , Ileum/pathology , Intestine, Small/drug effects , Lymph Nodes/drug effects , Lymph Nodes/metabolism , Lymphocytes/drug effects , Lymphocytes/metabolism , Male , Models, Animal , Mucins/biosynthesis , Paneth Cells/drug effects , Paneth Cells/metabolism , Peptides/genetics , Peptides/metabolism , Permeability , Phenotype , Phylogeny , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats, Wistar , Tight Junction Proteins/metabolism
4.
Crit Rev Food Sci Nutr ; 59(8): 1347-1356, 2019.
Article in English | MEDLINE | ID: mdl-29236523

ABSTRACT

Inflammatory Bowel Diseases (IBD) are increasing sharply, and the common medications are not effective for most patients. Vitamin D (VD) has been considerate to reduce inflammatory processes and may be helpful in IBD. The aim of this review was to perform an update on the potential role of VD in the IBD. We performed a search for articles associating VD and IBD published in MEDLINE-PubMed and EMBASE. The focused question used for the search was "What is the association between Inflammatory Bowel Disease and Vitamin D?" The exclusion criteria for this search were studies not in English, editorials, case reports, or poster presentations. VD prevents the inflammatory process such as negatively interfering with the release of Interleukin (IL)-1, IL-6, and Tumour Necrosis Factor-α; enhancing the function of the intestinal epithelial barrier; decreasing the occurrence of apoptosis; stimulating Toll-Like Receptor-4; inducing the production of an antimicrobial peptide in Paneth cells. Furthermore, deficiency of VD is related to the severity of the symptoms and increased the risk of cancer and surgery. In conclusion, VD shows a potential role in the management of IBD, the supplementation is inexpensive, safe, and leads to improvement of the quality of life.


Subject(s)
Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/immunology , Vitamin D/immunology , Vitamin D/therapeutic use , Antimicrobial Cationic Peptides/metabolism , Apoptosis/drug effects , Colitis, Ulcerative/drug therapy , Colitis, Ulcerative/immunology , Crohn Disease/drug therapy , Databases, Factual , Dietary Supplements , Humans , Interleukin-1/metabolism , Interleukin-6/metabolism , Intestinal Mucosa/drug effects , Paneth Cells/metabolism , Quality of Life , Toll-Like Receptor 4 , Tumor Necrosis Factor-alpha/metabolism , Vitamin D/metabolism
5.
Gastroenterology ; 156(4): 1098-1111, 2019 03.
Article in English | MEDLINE | ID: mdl-30452920

ABSTRACT

BACKGROUND & AIMS: Activating transcription factor 4 (ATF4) regulates genes involved in the inflammatory response, amino acid metabolism, autophagy, and endoplasmic reticulum stress. We investigated whether its activity is altered in patients with inflammatory bowel diseases (IBDs) and mice with enterocolitis. METHODS: We obtained biopsy samples during endoscopy from inflamed and/or uninflamed regions of the colon from 21 patients with active Crohn's disease (CD), 22 patients with active ulcerative colitis (UC), and 38 control individuals without IBD and of the ileum from 19 patients with active CD and 8 individuals without IBD in China. Mice with disruption of Atf4 specifically in intestinal epithelial cells (Atf4ΔIEC mice) and Atf4-floxed mice (controls) were given dextran sodium sulfate (DSS) to induce colitis. Some mice were given injections of recombinant defensin α1 (DEFA1) and supplementation of l-alanyl-glutamine or glutamine in drinking water. Human and mouse ileal and colon tissues were analyzed by quantitative real-time polymerase chain reaction, immunoblots, and immunohistochemistry. Serum and intestinal epithelial cell (IEC) amino acids were measured by high-performance liquid chromatography-tandem mass spectrometry. Levels of ATF4 were knocked down in IEC-18 cells with small interfering RNAs. Microbiomes were analyzed in ileal feces from mice by using 16S ribosomal DNA sequencing. RESULTS: Levels of ATF4 were significantly decreased in inflamed intestinal mucosa from patients with active CD or active UC compared with those from uninflamed regions or intestinal mucosa from control individuals. ATF4 was also decreased in colonic epithelia from mice with colitis vs mice without colitis. Atf4ΔIEC mice developed spontaneous enterocolitis and colitis of greater severity than control mice after administration of DSS. Atf4ΔIEC mice had decreased serum levels of glutamine and reduced levels of antimicrobial peptides, such as Defa1, Defa4, Defa5, Camp, and Lyz1, in ileal Paneth cells. Atf4ΔIEC mice had alterations in ileal microbiomes compared with control mice; these changes were reversed by administration of glutamine. Injections of DEFA1 reduced the severity of spontaneous enteritis and DSS-induced colitis in Atf4ΔIEC mice. We found that expression of solute carrier family 1 member 5 (SLC1A5), a glutamine transporter, was directly regulated by ATF4 in cell lines. Overexpression of SLC1A5 in IEC-18 or primary IEC cells increased glutamine uptake and expression of antimicrobial peptides. Knockdown of ATF4 in IEC-18 cells increased expression of inflammatory cytokines, whereas overexpression of SLC1A5 in the knockdown cells reduced cytokine expression. Levels of SLC1A5 were decreased in inflamed intestinal mucosa of patients with CD and UC and correlated with levels of ATF4. CONCLUSIONS: Levels of ATF4 are decreased in inflamed intestinal mucosa from patients with active CD or UC. In mice, ATF4 deficiency reduces glutamine uptake by intestinal epithelial cells and expression of antimicrobial peptides by decreasing transcription of Slc1a5. ATF4 might therefore be a target for the treatment of IBD.


Subject(s)
Activating Transcription Factor 4/deficiency , Antimicrobial Cationic Peptides/metabolism , Colitis, Ulcerative/metabolism , Crohn Disease/metabolism , Glutamine/metabolism , Activating Transcription Factor 4/genetics , Activating Transcription Factor 4/metabolism , Adolescent , Adult , Amino Acid Transport System ASC/genetics , Amino Acid Transport System ASC/metabolism , Animals , Case-Control Studies , Cell Line , Colitis/chemically induced , Colitis/metabolism , Colitis, Ulcerative/blood , Colitis, Ulcerative/pathology , Colon/cytology , Colon/metabolism , Crohn Disease/blood , Crohn Disease/pathology , Epithelial Cells , Female , Gene Knockdown Techniques , Glutamine/blood , Glutamine/pharmacology , Humans , Ileum/cytology , Ileum/metabolism , Ileum/microbiology , Intestinal Mucosa/metabolism , Male , Mice , Microbiota/drug effects , Middle Aged , Minor Histocompatibility Antigens/genetics , Minor Histocompatibility Antigens/metabolism , Paneth Cells/metabolism , Young Adult
6.
Biochem Biophys Res Commun ; 490(2): 253-259, 2017 08 19.
Article in English | MEDLINE | ID: mdl-28606477

ABSTRACT

Total parenteral nutrition (TPN) is a life-saving therapy for patients with gastrointestinal dysfunction or failure. Long-term TPN impairs gut barrier function and contributes to infections and poor clinical outcomes. However, the underlying mechanisms of TPN-related gut barrier damage have not been fully elucidated, and effective measures are still rare. Here, we compared the effects of a predominantly n-6 polyunsaturated fatty acids emulsion (PUFAs; Intralipid) and a lipid emulsion containing n-3 PUFAs (Intralipid plus Omegaven) on antimicrobial peptides produced by Paneth cells. Our results show for the first time that n-3 PUFAs markedly ameliorated intestine atrophy, and increased protein levels of lysozyme, RegIIIγ, and α-cryptdin 5, and their mRNA expression, compared to the n-6 PUFAs emulsion. Importantly, our study reveals that downregulation of IL-22 and phosphorylated Stat3 (p-Stat3) is associated with Paneth cell dysfunction, which may mediate TPN-related gut barrier damage. Lastly, n-3 PUFAs upregulated levels of IL-22 and increased the p-Stat3/Stat3 ratio in ileal tissue, suggesting that n-3 PUFAs improve Paneth cell function through activation of the IL-22/Stat3 pathway. Therefore, our study provides a cogent explanation for the beneficial effects of n-3 PUFAs, and indicates the IL-22/Stat3 pathway as a promising target in the treatment of TPN-related gut barrier damage.


Subject(s)
Fatty Acids, Omega-3/pharmacology , Interleukins/metabolism , Paneth Cells/drug effects , Parenteral Nutrition, Total , Phospholipids/pharmacology , STAT3 Transcription Factor/metabolism , Soybean Oil/pharmacology , Animals , Emulsions/administration & dosage , Emulsions/pharmacology , Fatty Acids, Omega-3/administration & dosage , Lipids , Male , Mice , Mice, Inbred C57BL , Models, Animal , Paneth Cells/metabolism , Phospholipids/administration & dosage , Soybean Oil/administration & dosage , Interleukin-22
7.
Nihon Rinsho Meneki Gakkai Kaishi ; 39(6): 522-527, 2016.
Article in Japanese | MEDLINE | ID: mdl-28049961

ABSTRACT

The intestinal epithelium constitutes a physical barrier between inner and outer side of our body. It also functions as a "hub" which connects factors that determine the development of inflammatory bowel disease, such as microbiota, susceptibility genes, and host immune response. Accordingly, recent studies have implicated and further featured the role of intestinal epithelial cell dysfunction in the pathophysiology of inflammatory bowel disease. For example, mucin producing goblet cells are usually "depleted" in ulcerative colitis patients. Studies have shown that those goblet cells exhibit various immune-regulatory functions in addition to mucin production, such as antigen presentation or cytokine production. Paneth cells are another key cell lineage that has been deeply implicated in the pathophysiology of Crohn's disease. Several susceptibility genes for Crohn's disease may lead to impairment of anti-bacterial peptide production and secretion by Paneth cells. Also, other susceptibility genes may determine the survival of Paneth cells, which leads to reduced Paneth cell function in the patient small intestinal mucosa. Further studies may reveal other unexpected roles of the intestinal epithelium in the pathophysiology of inflammatory bowel disease, and may help to develop alternative therapies targeted to intestinal epithelial cell functions.


Subject(s)
Epithelial Cells/physiology , Inflammatory Bowel Diseases/etiology , Intestines/cytology , Antigen Presentation , Antimicrobial Cationic Peptides/metabolism , Cytokines/biosynthesis , Gastrointestinal Microbiome , Genetic Predisposition to Disease/genetics , Goblet Cells/metabolism , Goblet Cells/pathology , Goblet Cells/physiology , Humans , Immunity , Inflammatory Bowel Diseases/pathology , Inflammatory Bowel Diseases/therapy , Molecular Targeted Therapy , Mucins/biosynthesis , Paneth Cells/metabolism , Paneth Cells/physiology
8.
Amino Acids ; 46(10): 2403-13, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25023447

ABSTRACT

This study was conducted to determine effects of dietary supplementation with 1 % L-glutamine for 14 days on the abundance of intestinal bacteria and the activation of intestinal innate immunity in mice. The measured variables included (1) the abundance of Bacteroidetes, Firmicutes, Lactobacillus, Streptococcus and Bifidobacterium in the lumen of the small intestine; (2) the expression of toll-like receptors (TLRs), pro-inflammatory cytokines, and antibacterial substances secreted by Paneth cells and goblet cells in the jejunum, ileum and colon; and (3) the activation of TLR4-nuclear factor kappa B (NF-κB), mitogen-activated protein kinases (MAPK), and phosphoinositide-3-kinases (PI3K)/PI3K-protein kinase B (Akt) signaling pathways in the jejunum and ileum. In the jejunum, glutamine supplementation decreased the abundance of Firmicutes, while increased mRNA levels for antibacterial substances in association with the activation of NF-κB and PI3K-Akt pathways. In the ileum, glutamine supplementation induced a shift in the Firmicutes:Bacteroidetes ratio in favor of Bacteroidetes, and enhanced mRNA levels for Tlr4, pro-inflammatory cytokines, and antibacterial substances participating in NF-κB and JNK signaling pathways. These results indicate that the effects of glutamine on the intestine vary with its segments and compartments. Collectively, dietary glutamine supplementation of mice beneficially alters intestinal bacterial community and activates the innate immunity in the small intestine through NF-κB, MAPK and PI3K-Akt signaling pathways.


Subject(s)
Dietary Supplements , Glutamine/administration & dosage , Immunity, Innate , Immunologic Factors/administration & dosage , Intestinal Mucosa/microbiology , Intestine, Small/microbiology , Animals , Bacteroidetes/classification , Bacteroidetes/growth & development , Bacteroidetes/immunology , Bacteroidetes/isolation & purification , Colon/immunology , Colon/metabolism , Cytokines/genetics , Cytokines/metabolism , Female , Goblet Cells/immunology , Goblet Cells/metabolism , Gram-Positive Bacteria/classification , Gram-Positive Bacteria/growth & development , Gram-Positive Bacteria/immunology , Gram-Positive Bacteria/isolation & purification , Ileum/cytology , Ileum/immunology , Ileum/metabolism , Ileum/microbiology , Intestinal Mucosa/cytology , Intestinal Mucosa/immunology , Intestinal Mucosa/metabolism , Intestine, Small/cytology , Intestine, Small/immunology , Intestine, Small/metabolism , Jejunum/cytology , Jejunum/immunology , Jejunum/metabolism , Jejunum/microbiology , Mice, Inbred ICR , Molecular Typing , Paneth Cells/immunology , Paneth Cells/metabolism , Random Allocation , Signal Transduction , Specific Pathogen-Free Organisms , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism
9.
Free Radic Biol Med ; 67: 265-77, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24275540

ABSTRACT

Selenoproteins are candidate mediators of selenium-dependent protection against tumorigenesis and inflammation in the gut. Expression and roles of only a limited number of intestinal selenoproteins have been described so far. Selenoprotein S (SelS) has been linked to various inflammatory diseases and is suggested to be involved in endoplasmic reticulum (ER) homeostasis regulation and antioxidative protection in a cell-type-dependent manner, but its protein expression, regulation, and function in the gut are not known. We here analyzed the expression and localization of SelS in the healthy and inflamed gut and studied its regulation and function in intestinal epithelial cell lines. SelS was expressed in the intestinal epithelium of the small and large intestine and colocalized with markers of Paneth cells and macrophages. It was upregulated in inflamed ileal tissue from Crohn's disease patients and in two models of experimental colitis in mice. We detected SelS in colorectal cell lines, where it colocalized with the ER marker calnexin. SelS protein expression was unaffected by enterocytic differentiation but increased in response to selenium supplementation and after treatment with the ER stress inducer tunicamycin. On the other hand, depletion of SelS in LS174T, HT29, and Caco-2 cells by RNA interference did not cause or modulate ER stress and had no effect on hydrogen peroxide-induced cell death. In summary, we introduce SelS as a novel marker of Paneth cells and intestinal ER stress. Although it is upregulated in Crohn's disease, its role in disease etiology remains to be established.


Subject(s)
Crohn Disease/metabolism , Endoplasmic Reticulum Stress/drug effects , Epithelial Cells/metabolism , Intestinal Mucosa/metabolism , Membrane Proteins/metabolism , Selenoproteins/metabolism , Tunicamycin/pharmacology , Animals , Biomarkers/metabolism , Biopsy , Calnexin/genetics , Calnexin/metabolism , Cell Line , Crohn Disease/pathology , Epithelial Cells/pathology , Gene Expression , Humans , Intestines/pathology , Macrophages/metabolism , Macrophages/pathology , Membrane Proteins/genetics , Mice , Paneth Cells/metabolism , Paneth Cells/pathology , Selenoproteins/genetics
10.
Proc Natl Acad Sci U S A ; 99(24): 15451-5, 2002 Nov 26.
Article in English | MEDLINE | ID: mdl-12432102

ABSTRACT

The adult mouse intestine contains an intricate vascular network. The factors that control development of this network are poorly understood. Quantitative three-dimensional imaging studies revealed that a plexus of branched interconnected vessels developed in small intestinal villi during the period of postnatal development that coincides with assembly of a complex society of indigenous gut microorganisms (microbiota). To investigate the impact of this environmental transition on vascular development, we compared the capillary networks of germ-free mice with those of ex-germ-free animals colonized during or after completion of postnatal gut development. Adult germ-free mice had arrested capillary network formation. The developmental program can be restarted and completed within 10 days after colonization with a complete microbiota harvested from conventionally raised mice, or with Bacteroides thetaiotaomicron, a prominent inhabitant of the normal mouse/human gut. Paneth cells in the intestinal epithelium secrete antibacterial peptides that affect luminal microbial ecology. Comparisons of germ-free and B. thetaiotaomicron-colonized transgenic mice lacking Paneth cells established that microbial regulation of angiogenesis depends on this lineage. These findings reveal a previously unappreciated mechanism of postnatal animal development, where microbes colonizing a mucosal surface are assigned responsibility for regulating elaboration of the underlying microvasculature by signaling through a bacteria-sensing epithelial cell.


Subject(s)
Bacteroides/physiology , Intestine, Small/blood supply , Neovascularization, Physiologic/physiology , Paneth Cells/metabolism , Proteins/metabolism , alpha-Defensins/metabolism , Animals , Cell Differentiation , Cell Lineage , Defensins , Diphtheria Toxin/pharmacology , Germ-Free Life , Imaging, Three-Dimensional , Intestinal Mucosa/cytology , Intestinal Mucosa/growth & development , Intestine, Small/growth & development , Intestine, Small/microbiology , Intestine, Small/ultrastructure , Mice , Mice, Transgenic , Microvilli , Paneth Cells/cytology , Paneth Cells/drug effects , Peptide Fragments/pharmacology , Proteins/genetics , Specific Pathogen-Free Organisms
SELECTION OF CITATIONS
SEARCH DETAIL